MRI-guided laser ablation of neuroendocrine tumor hepatic metastases

Acta Radiologica Short Reports

Jukka Perälä⁴  Rauli Klemola³  Raija Kallio⁶  Chengli Li²  Ilkka Vihriälä⁵  Pasi I Salmela¹  Osmo Tervonen⁴  Roberto Blanco Sequeiros⁴ 

[1] Department of Medicine, Division of Endocrinology, Oulu University Hospital, Oulu, Finland

[2] Shandong Provincial Medical Imaging Research Institute, Shandong University, Jinan, Shandong, PR China

[3] Department of Radiology, Southern Ostrobothnia Hospital, Seinäjoki, Finland

[4] Department of Radiology, Oulu University Hospital, Oulu, Finland

[5] Department of Medicine, Central Ostrobothnia Hospital, Kokkola, Finland

[6] Department of Oncology, Oulu University Hospital, Finland

关键词: liver;    NET;    tumor;    ablation;    metastasis;    laser;    MRI;   

Others  :  923859
DOI  :  10.1177/2047981613499753

 received in 2013-02-27, accepted in 2013-07-10,  发布年份 2014

【 摘 要 】

Background Neuroendocrine tumors (NET) represent a therapeutically challenging and heterogeneous group of malignancies occurring throughoutthe body, but mainly in the gastrointestinal system.

Purpose To describe magnetic resonance imaging (MRI)-guided laser ablation of NET liver metastases and assess its role within thecurrent treatment options and methods.

Material and Methods Two patients with NET tumor hepatic metastases were treated with MRI-guided interstitial laser ablation (LITT). Three tumorswere treated. Clinical follow-up time was 10 years.

Results Both patients were successfully treated. There were no local recurrences at the ablation site during the follow-up. Bothpatients had survived at 10-year follow-up. One patient is disease-free.

Conclusion MRI-guided laser ablation can be used to treat NET tumor liver metastases but combination therapy and a rigorous follow-upschedule are recommended.

【 授权许可】

   
© The Foundation Acta Radiologica 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Yao JC, Hassan M, Phan A, et al . One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063–3072.
• [2]Bilimoria KY, Bentrem DJ, Wayne JD, et al . Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009; 249: 63–71.
• [3]Hauso O, Gustafsson BI, Kidd M, et al . Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113: 2655–2664.
• [4]Frilling A, Sotiropoulos GC, Li J, et al . Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 2010; 12: 361–379.
• [5]Veenendaal LM, Borel Rinkes IH, Lips CJ, et al . Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol 2006; 4: 35–35.
• [6]Chamberlain RS, Canes D, Brown KT, et al . Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190: 432–445.
• [7]Mayo SC, de Jong MC, Pulitano C, et al . Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010; 17: 3129–3136.
• [8]Harring TR, Nguyen NT, Goss JA, et al . Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review. Int J Hepatol 2011; 2011: 154541–154541.
• [9]Gurusamy KS, Ramamoorthy R, Sharma D, et al . Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev 2009, pp. CD007060–CD007060.
• [10]Wessels FJ, Schell SR . Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res 2001; 95: 8–12.
• [11]Lewis MA, Hubbard J . Multimodal liver-directed management of neuroendocrine hepatic metastases. Int J Hepatol 2011; 2011: 452343–452343.
• [12]Atwell TD, Charboneau JW, Que FG, et al . Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol 2005; 28: 409–421.
• [13]Therasse P, Arbuck SG, Eisenhauer EA, et al . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–216.
• [14]Stafford RJ, Fuentes D, Elliott AA, et al . Laser-induced thermal therapy for tumor ablation. Crit Rev Biomed Eng 2010; 38: 79–100.
• [15]Kickhefel A, Rosenberg C, Weiss CR, et al . Clinical evaluation of MR temperature monitoring of laser-induced thermotherapy in human liver using the proton-resonance-frequency method and predictive models of cell death. J Magn Reson Imaging 2011; 33: 704–712.
• [16]Kariniemi J, Ojala R, Hellstrom P, et al . MRI-guided percutaneous laser ablation of small renal cell carcinoma: Initial clinical experience. Acta Radiol 2010; 51: 467–472.
• [17]Vogl TJ, Straub R, Eichler K, et al . Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions). Radiology 2002; 225: 367–377.
• [18]Rieke V, Butts Pauly K . MR thermometry. J Magn Reson Imaging 2008; 27: 376–390.
• [19]Puls R, Langner S, Rosenberg C, et al . Laser ablation of liver metastases from colorectal cancer with MR thermometry: 5-year survival. J Vasc Interv Radiol 2009; 20: 225–234.
• [20]Germain D, Chevallier P, Laurent A, et al . MR monitoring of laser-induced lesions of the liver in vivo in a low-field open magnet: temperature mapping and lesion size prediction. J Magn Reson Imaging 2001; 13: 42–49.
• [21]Vogl TJ, Naguib NN, Eichler K, et al . Volumetric evaluation of liver metastases after thermal ablation: long-term results following MR-guided laser-induced thermotherapy. Radiology 2008; 249: 865–871.
• [22]Vogl TJ, Naguib NN, Zangos S, et al . Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 2009; 72: 517–528.
• [23]Sequeiros RB, Klemola R, Ojala R, et al . Percutaneous MR-guided discography in a low-field system using optical instrument tracking: a feasibility study. J Magn Reson Imaging 2003; 17: 214–219.
• [24]Kariniemi J, Blanco Sequeiros R, Ojala R, et al . MRI-guided abdominal biopsy in a 0.23-T open-configuration MRI system. Eur Radiol 2005; 15: 1256–1262.
• [25]Steward MJ, Warbey VS, Malhotra A, et al . Neuroendocrine tumors: role of interventional radiology in therapy. Radiographics 2008; 28: 1131–1145.
• [26]Tacke J, Adam G, Haage P, et al . MR-guided percutaneous cryotherapy of the liver: in vivo evaluation with histologic correlation in an animal model. J Magn Reson Imaging 2001; 13: 50–56.
• [27]Sequeiros RB, Kariniemi J, Ojala R, et al . Liver tumor laser ablation - increase in the subacute ablation lesion volume detected with post procedural MRI. Acta Radiol 2010; 51: 505–511.
• [28]Mack MG, Straub R, Eichler K, et al . Percutaneous MR imaging-guided laser-induced thermotherapy of hepatic metastases. Abdom Imaging 2001; 26: 369–374.
• [29]Lazebnik RS, Weinberg BD, Breen MS, et al . Sub-acute changes in lesion conspicuity and geometry following MR-guided radiofrequency ablation. J Magn Reson Imaging 2003; 18: 353–359.
• [30]Streitparth F, Knobloch G, Balmert D, et al . Laser-induced thermotherapy (LITT)–evaluation of a miniaturised applicator and implementation in a 1.0-T high-field open MRI applying a porcine liver model. Eur Radiol 2010; 20: 2671–2678.
• [31]Puls R, Stroszczynski C, Gaffke G, et al . Laser-induced thermotherapy (LITT) of liver metastases: MR-guided percutaneous insertion of an MRI-compatible irrigated microcatheter system using a closed high-field unit. J Magn Reson Imaging 2003; 17: 663–670.
• [32]Vogl TJ, Mack M, Eichler K, et al . Effect of laser-induced thermotherapy on liver metastases. Expert Rev Anticancer Ther 2006; 6: 769–774.
• [33]Ramage JK, Ahmed A, Ardill J, et al . Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012; 61: 6–32.